Accès ouvert déclaré 2023 article

Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey

Minako Iida, Kai‐Yan Liu, Xiao Jun Huang, He Huang, Yachiyo Kuwatsuka, Joon Ho Moon, Jong Wook Lee, Kavitha M. Lakshmi, Anthony J. Dodds, Leonie Wilcox, Bor‐Sheng Ko, Amir Ali Hamidieh, Maryam Behfar, Kim Wah Ho, Udomsak Bunworasate, Aloysius Yew Leng Ho, Tasneem Farzana, Joycelyn Sim, Phu Chi Dung, Mafruha Akter, Wasantha Ratnayake, Marjorie Rose Bravo, Aye Aye Gyi, Damai Santosa, Bishesh Sharma Poudyal, Khishigjargal Batshkh, Alok Srivastava, Shinichiro Okamoto, Yoshiko Atsuta

7Citations signalées, ce qui n’est pas une note de qualité

29Institutions déclarées

18Pays d’affiliation déclarés

Rattachement africain : jp, cn, kr, in, au, tw, ir, my, th, sg, pk, bd, lk, ph, mm, id, np, mn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

The number of hematopoietic stem cell transplantations (HCTs) is increasing annually worldwide, and the Asia-Pacific (AP) region is no exception. We report on the absolute number of HCTs in 2018 and 2019 and the trends in graft selection and disease indication in the past few decades. In 2018, 24,292 HCTs were performed in the AP region, of which 8,754 (36.0%) were autologous and 15,538 (64.0%) were allogeneic. Among the allogeneic HCTs, 10,552 (67.9%) of the recipients were related to their donors, whereas 4,986 (32.1%) were unrelated. In 2019, 27,583 HCTs were reported, of which 17,613 (63.9%) were allogeneic and 9,970 (36.1%) were autologous. Although, in 2010, there was a nearly equal number of related and unrelated HCTs, the difference has shown an annual increase, with more than double (2.05) the number of related than unrelated HCTs in 2019. Recent trends in the AP region show that peripheral blood has overwhelmingly surpassed the bone marrow as a graft source for both related and unrelated HCTs, with the haploidentical donor type being preferred; however, their trends in each country/region were quite different among countries/regions. In 2019, the main conditions requiring HCT were acute myelogenous leukemia (n=6,629 [24.0%]), plasma cell disorders (PCD) (n=4,935 [17.9%]), malignant lymphoma (ML) (n=4,106 [14.9%]), acute lymphoblastic leukemia (AML) (n=3,777 [13.7%]), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm (n=1,913 [6.9%]), severe aplastic anemia (n=1,671 [6.1%]), and hemoglobinopathy (n=910 [3.3%]). PCD and ML were the main indications for autologous HCT, and the number of PCD cases has grown more prominent than the corresponding of ML. The increased number of allogeneic transplants for hemoglobinopathy remains prominent, as well as that of AML and acute lymphocytic leukemia for the past 5 years. There was a significant regional variation in the number of facilities performing HCTs, ranging from one in Mongolia and Nepal to 313 in Japan, and differing regional densities varying from 0.1 in Indonesia and Pakistan to 24.7 in Japan. The total transplant density per 10 million population in each country/region also differed (0.2 in Indonesia and 627 in New Zealand). This annual Activity Survey aims to help all participating countries/regions understand the changes in HCT, serve as an asset in promoting HCT activities in the AP region, and be used as a reference for comparison with other registries from Europe and the United States.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey
Date Crossref: 01/01/2023
Éditeur: Asia-Pacific Blood and Marrow Transplantation Group
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Aichi Medical University Department of Promotion for Blood and Marrow Transplantation pays non établi dans la notice
Université ou école supérieure
Peking University Department of Hematology pays non établi dans la notice
Université ou école supérieure
Zhejiang University pays non établi dans la notice
Université ou école supérieure
Nagoya University Hospital Department of Advanced Medicine pays non établi dans la notice
Établissement de santé
Kyungpook National University Hospital Department of Internal Medicine pays non établi dans la notice
Établissement de santé
The Catholic University of Korea Seoul St. Mary's Hospital Seoul St. Mary's Hospital pays non établi dans la notice
Établissement de santé
Catholic University of Korea pays non établi dans la notice
Université ou école supérieure
Christian Medical College Department of Hematology pays non établi dans la notice
Université ou école supérieure
St Vincent's Hospital Sydney pays non établi dans la notice
Établissement de santé
St Vincent’s Private Hospital Sydney pays non établi dans la notice
Établissement de santé
National Taiwan University Hospital Department of Internal Medicine pays non établi dans la notice
Établissement de santé
Stem Cell Technology Research Center pays non établi dans la notice
Structure de recherche

Department of Promotion for Blood and Marrow Transplantation — Aichi Medical University, Department of Hematology — Peking University et Zhejiang University, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Hematopoietic Stem Cell Transplantation

Consulter la publication primaire Ouvrir le DOI